ReviewOpen biology2026
Molecular basis and therapeutic potential of sortase A inhibitors as new antibiotics against MDR pathogens.
Review in Open biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Attaching proteins to the cell surface presents a technical challenge to Gram-positive bacteria. A class of enzymes called sortases solves this challenge by covalently anchoring proteins, including an arsenal of virulence factors, to the cell wall. Most Gram-positive bacteria have multiple critical factors that are anchored in this manner and, coupled with the extracellular location of this reaction, make sortase an attractive target for the development of antibiotics. However, since sortase is neither essential nor itself a virulence factor, it is a very different sort of target compared to those investigated in other antibiotic strategies. This review explores the challenges of treating infection by Gram-positive pathogens, the importance of sortase-anchored proteins in the host-pathogen interaction and the known and probable antimicrobial effects of sortase inhibition for infections by Staphylococcus aureus, Streptococcus pyogenes, Bacillus anthracis, Listeria monocytogenes and other Gram-positive pathogens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.